Literature DB >> 15630506

Haemostatic abnormalities and thrombotic disorders in malignant lymphoma.

Tomohiro Sase1, Hideo Wada, Motoko Yamaguchi, Shoko Ogawa, Yuko Kamikura, Masakatsu Nishikawa, Toshihiro Kaneko, Yasunori Abe, Junji Nishioka, Tsutomu Nobori, Hiroshi Shiku.   

Abstract

We examined haemostatic abnormalities and thrombotic disorders in 217 patients with malignant lymphoma. Plasma levels of fibrinogen and D-dimer were significantly higher in patients with malignant lymphoma than in healthy subjects. The incidence of severe complications, such as disseminated intravascular coagulation (DIC) and interstitial pneumonia (IP), differed with each clinical stage or histological type, but they occurred frequently in stage IV or natural killer (NK) cell lymphoma. Plasma levels of fibrinogen degradation products (FDP) and D-dimer, leukocyte tissue factor (TF) mRNA and plasma TF antigen were significantly higher in stage IV than in stage I, II or III. Plasma levels of FDP, D-dimer, and leukocyte TF mRNA in NK cell lymphoma were markedly higher than in other types of lymphoma. Immunohistochemical staining of NK cell lymphoma revealed that granulocyte macrophage colony-stimulating factor was positive in tumour cells, whereas von Willebrand factor and TF were positive in vascular endothelial cells of surrounding tissue. Our results suggested that patients with stage IV disease and NK cell lymphoma were in abnormal thrombotic and haemostatic state, and may frequently develop DIC and IP. One of the mechanisms of DIC and IP may involve elevated cytokine production by lymphoma cells, which can stimulate the expression of TF in blood cells or surrounding tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630506     DOI: 10.1160/TH04-04-0260

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Disseminated intravascular coagulation in non-Hodgkin lymphoma.

Authors:  SungGi Chi; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2015-08-14       Impact factor: 2.490

Review 2.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

3.  National trends in hospital readmission following transsphenoidal surgery for pituitary lesions.

Authors:  Kelly A Shaftel; Tyler S Cole; Andrew S Little
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

4.  Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes.

Authors:  I M B Francischetti; K B Seydel; R Q Monteiro; R O Whitten; C R Erexson; A L L Noronha; G R Ostera; S B Kamiza; M E Molyneux; J M Ward; T E Taylor
Journal:  J Thromb Haemost       Date:  2006-09-26       Impact factor: 5.824

5.  Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients.

Authors:  Rachel E Tilley; Todd Holscher; Rajesh Belani; Jorge Nieva; Nigel Mackman
Journal:  Thromb Res       Date:  2008-02-11       Impact factor: 3.944

6.  Tissue factor procoagulant activity in the tumor cell lines and plasma of dogs with various malignant tumors.

Authors:  Kosuke Kobayashi; Kenji Baba; Masaya Igase; Hardany Primarizky; Yuki Nemoto; Takako Shimokawa Miyama; Satoshi Kambayashi; Takuya Mizuno; Masaru Okuda
Journal:  J Vet Med Sci       Date:  2019-10-15       Impact factor: 1.267

7.  The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients.

Authors:  Mark Jaradeh; Nausheen Baig; Emily Bontekoe; Mirjana Mitrovic; Darko Antic; Debra Hoppensteadt; Bulent Kantarcioglu; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.